What is NDC 66215-628?

66215-628 is the product NDC for UPTRAVI Titration Pack (selexipag) kit, listed with the FDA by Actelion Pharmaceuticals US, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.

What drug is associated with this NDC?

UPTRAVI Titration Pack (Selexipag).

Actelion Pharmaceuticals US, Inc., NDC labeler code 66215. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for UPTRAVI Titration Pack?

None: this is the only finished product listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

UPTRAVI Titration Pack NDC 66215-628 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)66215-628Labeler and product segments. Claims need a package NDC.

Product NDC at billing width66215-0628Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
66215-628-20	66215062820	1 KIT in 1 CARTON (66215-628-20) * 1 BOTTLE in 1 CARTON / 140 TABLET, COATED in 1 BOTTLE * 1 BOTTLE in 1 CARTON / 60 TABLET, COATED in 1 BOTTLEMarketed from Dec 21, 2015

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): UPTRAVI Titration Pack
Generic name (nonproprietary): selexipag
Dosage form: Kit
Labeler: Actelion Pharmaceuticals US, Inc.NDC labeler code 66215
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 207947
Marketing start: Dec 21, 2015
Listing expires: Dec 31, 2027
Identifiers: Product ID 66215-628_7c54a125-9778-41f5-b92c-181711e22e06SPL ID 7c54a125-9778-41f5-b92c-181711e22e06SPL set ID a7a23b87-f892-4e2c-8e2e-ebf841220f90RxCUI 1729007, 1729013, 1729027, 1729029, 1729031, 1729033, 1729045, 1729047, 1729051, 1729053, 1729055, 1729057, 1729059, 1729061, 1729063, 1729065, 1729075, 1729076, 2565271, 2565275, 2744282, 2744284, 2744286, 2744288UNII 5EXC0E384LUPC 0366215612064, 0366215610060, 0366215604069, 0366215910146, 0366215606063, 0366215614068, 0366215616062

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

NDC on a medical claim

N466215062820 followed by a unit qualifier and the quantity

Package 66215-0628-20. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 28, 2026.

Indications (excerpt from the label)

UPTRAVI is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I): In adults to delay disease progression and reduce the risk of hospitalization for PAH. ( 1.1 ) In pediatric patients aged 2 years and older. UPTRAVI reduces NT-proBNP and is expected to delay disease progression and reduce the risk of hospitalization for PAH. ( 1.1 ) 1.1 Pulmonary Arterial Hypertension Adult Patients UPTRAVI is indicated for the treatment of pulmonary arterial hypertension in adults (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH. Effectiveness of UPTRAVI tablets was established in a long-term study in ad…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 66215-628

What is NDC 66215-628?: 66215-628 is the product NDC for UPTRAVI Titration Pack (selexipag) kit, listed with the FDA by Actelion Pharmaceuticals US, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: UPTRAVI Titration Pack (Selexipag).
Who is the labeler?: Actelion Pharmaceuticals US, Inc., NDC labeler code 66215. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for UPTRAVI Titration Pack?: None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other NDCs under NDA 207947

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 207947
Product	Strength	Form · route	Labeler	Product NDC
Uptraviselexipag	Selexipag 600 ug/1	Tablet, CoatedOral	Actelion Pharmaceuticals US, Inc.	66215-606
Uptraviselexipag	Selexipag 200 ug/1	Tablet, CoatedOral	Actelion Pharmaceuticals US, Inc.	66215-602
Uptraviselexipag	Selexipag 400 ug/1	Tablet, CoatedOral	Actelion Pharmaceuticals US, Inc.	66215-604
Uptraviselexipag	Selexipag 800 ug/1	Tablet, CoatedOral	Actelion Pharmaceuticals US, Inc.	66215-608
Uptraviselexipag	Selexipag 1000 ug/1	Tablet, CoatedOral	Actelion Pharmaceuticals US, Inc.	66215-610
Uptraviselexipag	Selexipag 1200 ug/1	Tablet, CoatedOral	Actelion Pharmaceuticals US, Inc.	66215-612
Uptraviselexipag	Selexipag 1400 ug/1	Tablet, CoatedOral	Actelion Pharmaceuticals US, Inc.	66215-614
Uptraviselexipag	Selexipag 1600 ug/1	Tablet, CoatedOral	Actelion Pharmaceuticals US, Inc.	66215-616
Uptraviselexipag	Selexipag 150 ug/1	Tablet, Film coatedOral	Actelion Pharmaceuticals US, Inc.	66215-915
Uptraviselexipag	Selexipag 100 ug/1	Tablet, Film coatedOral	Actelion Pharmaceuticals US, Inc.	66215-910

UPTRAVI Titration Pack (Selexipag) NDC 66215-628